Sentinel lymph node biopsy (SLNB) for axillary lymph node staging in early
breast cancer has been widely recognized. The combination of radio-
colloids and
dye method is the best method recognized. The
reagents and equipment required in the process of the combined method are complex and expensive, so there are certain restrictions in the use of primary medical institutions. As a new tracer, fluorescent tracer technology has attracted much attention. We aimed to evaluate the feasibility and safety of
fluorescein for SLNB in
breast cancer. In this study, a total of 123 patients with
breast cancer were divided into group A (n = 67) and group B (n = 56). The efficacy of
Indocyanine green (ICG) combined with
methylene blue (group A) and
fluorescein combined with
methylene blue (group B) in SLNB of
breast cancer was compared, complications were observed at the same time. No local or systemic reactions were observed in the two groups. In group A, Sentinel lymph nodes of
breast cancer were detected in 63 patients, with a detection rate of 94.0% (63/67), a false-negative rate of 7.5% (4/53). In group B, Sentinel lymph nodes of
breast cancer were detected in 52 patients, with a detection rate of 92.9% (52/56), a false-negative rate of 7.5% (3/40). There was no significant difference in biopsy results between the two groups. This prospective clinical study suggests that SLNB using
fluorescein and ultraviolet LED light is feasible in
breast cancer patients. No adverse reactions were observed in this study, but larger studies are needed to properly assess the adverse reaction rate.